Angiogenesis in Nervous System Disorders

Neurosurgery

Volumn 53, Issue 6, 2003, Pages 1362-1376

  Zadeh, Gelareh ^a   Guha, Abhijit ^b,c   Berger, Mitchel S ^c   Hodge Jr , Charles J ^c   Dacey Jr , Ralph G ^c   Connolly Jr , E Sander ^c   Gunel, Murat ^c  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE

Author keywords

Angiogenesis; Angiopoietins; Antiangiogenic therapy Central nervous system; Vascular endothelial growth factor, Vasculogenesis

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AE 941; ALPHA INTERFERON; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOSTATIN; ATRASENTAN; CGS 27023A; CILENGITIDE; COMBRETASTATIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; L 778123; LONAFARNIB; MARIMASTAT; PENICILLAMINE; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; REBIMASTAT; SEMAXANIB; SQUALAMINE; SURAMIN; TANOMASTAT; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB;

ANGIOGENESIS; BRAIN BLOOD VESSEL; BRAIN INFARCTION; BRAIN SURGERY; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR MALFORMATION; CLINICAL TRIAL; DRUG EFFECT; EXTRACELLULAR MATRIX; HUMAN; MOLECULAR DYNAMICS; MOYAMOYA DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 0344875196     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000093425.98136.31     Document Type: Review

References (143)

1. Angelov L, Salhia B, Roncari L, McMahon G, Guha A: Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res 59:5536-5541, 1999.
2. Audero E, Cascone I, Zanon I, Previtali SC, Piva R, Schiffer D, Bussolino F: Expression of angiopoietin-1 in human glioblastomas regulates tumor-induced angiogenesis: In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 21:536-541, 2001.
3. Benezra R, Davis RL, Lassar A, Tapscott S, Thayer M, Lockshon D, Weintraub H: Id: A negative regulator of helix-loop-helix DNA binding proteins-Control of terminal myogenic differentiation. Ann N Y Acad Sci 599:1-11, 1990.
4. Benezra R, Rafii S, Lyden D: The Id proteins and angiogenesis. Oncogene 20:8334-8341, 2001.
5. Bennett S-S: Matrix Metalloproteinases and their Inhibitors in Angiogenesis: Tumor Angiogenesis and Microcirculation. New York, Marcel Dekker, 2001.
6. Brat DJ, Van Meir EG: Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: A new world of angiogenesis research. Am J Pathol 158:789-796, 2001.
7. Breier G, Albrecht U, Sterrer S, Risau W: Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114:521-532, 1992.
8. Brem S: Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control 6:436-458, 1999.
9. Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO: Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 276: 26516-26525, 2001.
10. Carmeliet P, Collen D: Vascular development and disorders: Molecular analysis and pathogenic insights. Kidney Int 53:1519-1549, 1998.
11. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000.
12. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G, Ploplis V, Muller M, Nagy A, Plow E, Gerard R, Edgington T, Risau W, Collen D: Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 811:191-206, 1997.
13. Cha S, Knopp EA, Johnson G, Litt A, Glass J, Gruber ML, Lu S, Zagzag D: Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 21:881-890, 2000.
14. Chen EY, Fujinaga M, Giaccia AJ: Hypoxic microenvironment within an embryo induces apoptosis and is essential for proper morphological development. Teratology 60:215-225, 1999.
15. Coffin JD, Poole TJ: Embryonic vascular development: Immunohistochemical identification of the origin and subsequent morphogenesis of the major vessel primordia in quail embryos. Development 102:735-748, 1988.
16. Craig HD, Gunel M, Cepeda O, Johnson EW, Ptacek L, Steinberg GK, Ogilvy CS, Berg MJ, Crawford SC, Scott RM, Steichen-Gersdorf E, Sabroe R, Kennedy CT, Mettler G, Beis MJ, Fryer A, Awad IA, Lifton RP: Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet 7:1851-1858, 1998.
17. Croll SD, Wiegand SJ: Vascular growth factors in cerebral ischemia. Mol Neurobiol 23:121-135, 2001.
18. D'Amore PA: Mechanisms of endothelial growth control. Am J Respir Cell Mol Biol 6:1-8, 1992.
19. Darland DC, D'Amore PA: Endothelial cells and pericytes in tumor vasculature, in Voest EE, D'Amore PA (eds): Tumor Angiogenesis and Microcirculation. New York, Dekker, 2001.
20. Davenport WJ, Siegel AM, Dichgans J, Drigo P, Mammi I, Pereda P, Wood NW, Rouleau GA: CCM1 gene mutations in families segregating cerebral cavernous malformations. Neurology 56:540-543, 2001.
21. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169, 1996.
22. Ding H, Roncari L, Wu X, Lau N, Shannon P, Nagy A, Guha A: Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neurooncol 3:1-10, 2001.
23. Drake CJ, LaRue A, Ferrara N, Little CD: VEGF regulates cell behavior during vasculogenesis. Dev Biol 224:178-188, 2000.
24. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML: tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7:1471-1480, 1992.
25. Dunn IF, Heese O, Black PMcL: Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 50:121-137, 2000.
26. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995.
27. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van De Water L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174:12750-12780, 1991.
28. Eke A, Conger KA, Anderson M, Garcia JH: Histologic assessment of neurons in rat models of cerebral ischemia. Stroke 21:299-304, 1990.
29. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K: Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14:2475-2483, 1997.
30. Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18:7514-7526, 1999.
31. Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A: Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer 81:118-124, 1999.
32. Ferrara N: VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol 11:617-624, 2000.
33. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803, 2002.
34. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996.
35. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PMcL, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715, 2000.
36. Flamme I, Frohlich T, von Reutern M, Kappel A, Damert A, Risau W: HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels. Mech Dev 63:51-60, 1997.
37. Folkman J: Tumor angiogenesis, in Klein G, Weinhouse S (eds): Advances in Cancer Research. New York, Academic Press, 1974, pp 43-52.
38. Folkman J: Angiogenesis-dependent diseases. Semin Oncol 28:536-542, 2001.
39. Fukui M, Kono S, Sueishi K, Ikezaki K: Moyamoya disease. Neuropathology 20[Suppl]:S61-S64, 2000.
40. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA: Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 87:603-607, 2000.
41. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N: VEGF is required for growth and survival in neonatal mice. Development 126:1149-1159, 1999.
42. Gospodarowicz D, Abraham JA, Schilling J: Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci U S A 86:7311-7315, 1989.
43. Guha A: Platelet-derived growth factor: A general review with emphasis on astrocytomas. Pediatr Neurosurg 17:14-20, 1991.
44. Gunel M, Awad IA, Finberg K, Anson JA, Steinberg GK, Batjer HH, Kopitnik TA, Morrison L, Giannotta SL, Nelson-Williams C, Lifton RP: A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans. N Engl J Med 334:946-951, 1996.
45. Gunel M, Awad IA, Finberg K, Steinberg GK, Craig HD, Cepeda O, Nelson-Williams C, Lifton RP: Genetic heterogeneity of inherited cerebral cavernous malformation. Neurosurgery 38:1265-1271, 1996.
46. Gunel M, Laurans MS, Shin D, DiLuna ML, Voorhees J, Choate K, Nelson-Williams C, Lifton RP: KRIT1, a gene mutated in cerebral cavernous malformation, encodes a microtubule-associated protein. Proc Natl Acad Sci U S A 99:10677-10682, 2002.
47. Hanahan D: Signalling vascular morphogenesis and maintenance. Science 277:48-50, 1997.
48. Hatva E, Bohling T, Jääskeläinen J, Persico MG, Haltia M, Alitalo K: Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 148:763-775, 1996.
49. Hatva E, Jääskeläinen J, Hirvonen H, Alitalo K, Haltia M: Tie endothelial cell-specific receptor tyrosine kinase is upregulated in the vasculature of arteriovenous malformations. J Neuropathol Exp Neurol 55:1124-1133, 1996.
50. Hayashi T, Abe K, Itoyama Y: Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab 18:887-895, 1998.
51. Hayashi T, Abe K, Suzuki H, Itoyama Y: Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 28:2039-2044, 1997.
52. Hayman LA, Evans RA, Ferrell RE, Fahr LM, Ostrow P, Riccardi VM: Familial cavernous angiomas: Natural history and genetic study over a 5-year period. Am J Med Genet 11:147-160, 1982.
53. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316, 1999.
54. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998, 1999.
55. Holash J, Wiegand SJ, Yancopoulos GD: New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356-5362, 1999.
56. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW: The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814, 1991.
57. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA: Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265:1883-1885, 1994.
58. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761-19766, 1995.
59. Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P: Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest 79:417-425, 1999.
60. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189-195, 1996.
61. Jones N, Dumont DJ: The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene 17:1097-1108, 1998.
62. Jones N, Dumont DJ: Tek/Tie2 signaling: New and old partners. Cancer Metastasis Rev 19:13-17, 2000.
63. Kilic T, Pamir MN, Kullu S, Eren F, Ozek MM, Black PMcL: Expression of structural proteins and angiogenic factors in cerebrovascular anomalies. Neurosurgery 46:1179-1192, 2000.
64. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY: Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 19: 4549-4552, 2000.
65. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY: Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/ Akt signal transduction pathway. Circ Res 86:24-29, 2000.
66. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993.
67. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T, Ushio Y: Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61:6248-6254, 2001.
68. Kono S, Oka K, Sueishi K, Sonobe M: Histopathological studies on spontaneous vault moyamoya and revascularized collaterals formed by encephalomyosynangiosis. Clin Neurol Neurosurg 99[Suppl 2]:S209-S212, 1997.
69. Kontos C, Stauffer T, Yang W-P, York J, Huang L, Blanar M, Meyer T, Peters K: Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for the activation of phosphatidylinositol 3-kinase and Akt. Mol Cell Biol 18:4131-4140, 1998.
70. Kotch LE, Iyer NV, Laughner E, Semenza GL: Defective vascularization of HIF-1α-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 209:254-267, 1999.
71. Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M: VEGF and fit: Expression time kinetics in rat brain infarct. Stroke 27:1865-1873, 1996.
72. Krieg M, Marti HH, Plate KH: Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 92:3388-3393, 1998.
73. Krupinski J, Issa R, Bujny T, Slevin M, Kumar P, Kumar S, Kaluza J: A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke 28:564-573, 1997.
74. Lee YM, Jeong CH, Koo SY, Son MJ, Song HS, Bae SK, Raleigh JA, Chung HY, Yoo MA, Kim KW: Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: A possible signal for vessel development. Dev Dyn 220:175-186, 2001.
75. Lennmyr F, Ata KA, Funa K, Olsson Y, Terent A: Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J Neuropathol Exp Neurol 57:874-882, 1998.
76. Levy AP, Levy NS, Wegner S, Goldberg MA: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270:13333-13340, 1995.
77. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9:49-58, 1998.
78. Lin TN, Wang CK, Cheung WM, Hsu CY: Induction of angiopoietin and Tie receptor mRNA expression after cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 20:387-395, 2000.
79. Lucas M, Solano F, Zayas MD, Garcia-Moreno JM, Gamero MA, Costa AF, Izquierdo G: Spanish families with cerebral cavernous angioma do not bear 742C→T Hispanic American mutation of the KRIT1 gene. Ann Neurol 47:836, 2000 (letter).
80. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA: Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 19:267-284, 1999.
81. Machein MR, Plate KH: VEGF in brain tumors. J Neurooncol 50:109-120, 2000.
82. Madri JA, Pratt BM, Tucker AM: Phenotypic modulation of endothelial cells by transforming growth factor-β depends upon the composition and organization of the extracellular matrix. J Cell Biol 106:1375-1384, 1988.
83. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997.
84. Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS: Vascular morphogenesis: Tales of two syndromes. Hum Mol Genet 12:R97-R112, 2003.
85. Marti HH, Risau W: Angiogenesis in ischemic disease. Thromb Haemost 82 [Suppl 1]:44-52, 1999.
86. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Strafford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 94:8104-8109, 1997.
87. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, et al.: Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345-351, 1994.
88. Meneses PI, Abrey LE, Hajjar KA, Gultekin SH, Duvoisin RM, Berns KI, Rosenfeld MR: Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clin Cancer Res 5:3689-3694, 1999.
89. Merwin JR, Newman W, Beall LD, Tucker A, Madri J: Vascular cells respond differentially to transforming growth factors β1 and β2 in vitro. Am J Pathol 138:37-51, 1991.
90. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A 83:7297-7301, 1986.
91. Muller G, Behrens J, Nussbaumer U, Bohlen P, Birchmeier W: Inhibitory action of transforming growth factor β on endothelial cells. Proc Natl Acad Sci U S A 84:5600-5604, 1987.
92. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341:309-315, 1998.
93. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y: Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274:15732-15739, 1999.
94. Papetti M, Herman IM: Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282;C947-C970, 2002.
95. Patan S: Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 50:1-15, 2000.
96. Plate KH: Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 58:313-320, 1999.
97. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520-529, 1994.
98. Poole TJ, Coffin JD: Developmental angiogenesis: Quail embryonic vasculature. Scan Microsc 2:443-448, 1988.
99. Poole TJ, Coffin JD: Vasculogenesis and angiogenesis: Two distinct morphogenetic mechanisms establish embryonic vascular pattern. J Exp Zool 251:224-231, 1989.
100. Pore N, Liu S, Haas-Kogan DA, O'Rourke DM, Maity A: PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 63:236-241, 2003.
101. Puduvalli VK, Sawaya R: Antiangiogenesis: Therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50:189-200, 2000.
102. Ribatti D, Mancini L, Roncali L, Nico B, Bertossi M: Morphometric analysis on the effects of hypoxia during the central nervous system vasculogenesis. Int J Microcirc Clin Exp 8:135-142, 1989.
103. Risau W: Embryonic angiogenesis factors. Pharmacol Ther 51:371-376, 1991.
104. Risau W: Mechanisms of angiogenesis. Nature 386:671-674, 1997.
105. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 11:73-91, 1995.
106. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29:1020-1030, 1998.
107. Rothbart D, Awad IA, Lee J, Kim J, Harbaugh R, Criscuolo GR: Expression of angiogenic factors and structural proteins in central nervous system vascular malformations. Neurosurgery 38:915-925, 1996.
108. Ryan HE, Lo J, Johnson RS: HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005-3015, 1998.
109. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393-401, 1996.
110. Schmidt-Lademann S, Stoeter P, Voigt K: Embryonal and fetal development of capillaries: Microangiographic investigations-Part II: The telencephalon. Diagn Imaging 49:177-187, 1980.
111. Serebriiskii I, Estojak J, Sonoda G, Testa JR, Golemis EA: Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene 15:1043-1049, 1997.
112. Shenkar R, Elliott JP, Diener K, Gault J, Hu LJ, Cohrs RJ, Phang T, Hunter L, Breeze RE, Awad IA: Differential gene expression in human cerebrovascular malformations. Neurosurgery 52:465-478, 2003.
113. Sinor AD, Irvin SM, Cobbs CS, Chen J, Graham SH, Greenberg DA: Hypoxic induction of vascular endothelial growth factor (VEGF) protein in astroglial cultures. Brain Res 812:289-291, 1998.
114. Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E: Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia. Mol Cell Biol 18:3112-3119, 1998.
115. Stein I, Neeman M, Shweiki D, Itin A, Keshet E: Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 15:5363-5368, 1995.
116. Stewart PA, Wiley MJ: Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: A study using quail-chick transplantation chimeras. Dev Biol 84:183-192, 1981.
117. Stoeter P, Schmidt-Lademann S, Voigt K: Comparative microangiographic and histologic studies of the embryonal development of intracerebral capillaries. Neuroradiology 16:620-624, 1978.
118. Stoeter P, Schmidt-Lademann S, Voigt K: Embryonal and fetal development of capillaries: Microangiographic investigations-Part I: The brain stem. Diagn Imaging 49:131-140, 1980.
119. Stratmann A, Risau W, Plate KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459-1466, 1998.
120. Symon L, Lassen NA, Astrup J, Branston NM: Thresholds of ischaemia in brain cortex. Adv Exp Med Biol 94:775-782, 1977.
121. Takahashi A, Sawamura Y, Houkin K, Kamiyama H, Abe H: The cerebro-spinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett 160:214-216, 1993.
122. Thomas KA: Fibroblast growth factors. FASEB J 1:434-440, 1987.
123. Thurston G: Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat 200:575-580, 2002.
124. Tsai JC, Goldman CK, Gillespie GY: Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 82:864-873, 1995.
125. Tymianski M, Wallace MC, Spigelman I, Uno M, Carlen PL, Tator CH, Charlton MP: Cell-permeant Ca2+ chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in vivo. Neuron 11:221-235, 1993.
126. Uranishi R, Baev NI, Kim JH, Awad IA: Vascular smooth muscle cell differentiation in human cerebral vascular malformations. Neurosurgery 49:671-680, 2001.
127. Uranishi R, Baev NI, Ng PY, Kim JH, Awad IA: Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations. Neurosurgery 48:359-368, 2001.
128. van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, Tumas D, Gerlai R, Williams SP, van Lookeren Campagne M, Ferrara N: VEGF antagonism reduces edema formation and tissue damage after ischemia/ reperfusion injury in the mouse brain. J Clin Invest 104:1613-1620, 1999.
129. Vikkula M, Boon LM, Carraway KL III, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR: Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87:1181-1190, 1996.
130. Vikkula M, Boon LM, Mulliken JB: Molecular genetics of vascular malformations. Matrix Biol 20:327-335, 2001.
131. Visconti RP, Richardson CD, Sato TN: Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 99:8219-8224, 2002.
132. Ward NL, Dumont DJ: The angiopoietins and Tie2/Tek: Adding to the complexity of cardiovascular development. Semin Cell Dev Biol 13:19-27, 2002.
133. Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors: Pathobiological and clinical aspects. J Neurooncol 32:253-265, 1997.
134. Wilting J, Christ B: Embryonic angiogenesis: A review. Naturwissenschaften 83:153-164, 1996.
135. Wilting J, Brand-Saberi B, Kurz H, Christ B: Development of the embryonic vascular system. Cell Mol Biol Res 41:219-232, 1995.
136. Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55:1358-1364, 1995.
137. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
138. Yoshimoto T, Houkin K, Takahashi A, Abe H: Angiogenic factors in moyamoya disease. Stroke 27:2160-2165, 1996.
139. Yurchenco PD, Schittny JC: Molecular architecture of basement membranes. FASEB J 4:1577-1590, 1990.
140. Zadeh G, Guha A: Neoangiogenesis in human astrocytomas: Expression and functional role of angiopoietins and their cognate receptors. Front Biosci 8: E128-E137, 2003.
141. Zadeh G, Sabha N, Kontos C, Guha A: Targeting Tie2 receptor in astrocytomas. Am J Pathol (in press).
142. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD, Grumet M: In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159:391-400, 1999.
143. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, Zhang R, Goussev A, Powers C, Yeich T, Chopp M: Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 22:379-392, 2002.